Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

LORAZEPAM

All injection strengths: Limited Use (codes 481)

Other products in the same Health Canada class (N05B) — coverage varies; not interchangeable

  • Buspirone (Buspar): general benefit, Not a benefit

Lorazepam Injection USP · DIN 02243278 · 4mg/mL · injection solution (with preservative)

Limited Use — Reason for Use code 481 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 481 required
Write on scriptLU code 481 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 481
Reason for Use code 481 For the management of patients receiving palliative care*. Coverage limit: LU Authorization Period: 1 year Coverage limit: *The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Lorazepam Injection USP · DIN 02243278 Manufacturer: Sandoz Canada Inc.; listing date 2017-02-28 Health Canada: Marketed since 2005-09-21 · brand LORAZEPAM INJECTION USP · ATC N05BA06 LORAZEPAM · form Solution · route Intravenous, Intramuscular · ingredients LORAZEPAM 4 MG/ML · company Sandoz canada incorporated · schedule Targeted substances (cdsa iv)
Check this DIN again · Health Canada product record

Lorazepam Injection USP: Formulary list price $19.0800/unit (unit not stated in source; not the patient's cost)

Ministry pays: $19.0800 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67176 · Verify on the e-Formulary ↗ (DIN 02243278)

Source record
DIN 02243278: Lorazepam Injection USP Raw flags: sec12=Y, sec3=Y Item: 282400076; group id 522; item number 1412; lccId 00275; manufacturer id SDZ Source form: Inj Sol (with preservative); strength: 4mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $19.0800; ministry $19.0800 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243278 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67176
Interchangeable products
Ativan · DIN 02041405 · not recorded Lorazepam Injection, USP · DIN 02550962 · $19.0800
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (28:24 Sedatives and Hypnotics) and how they are covered

Matched class: 28:24 Sedatives and Hypnotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: NITRAZEPAM, PHENOBARBITAL, TEMAZEPAM Some products covered without a code (check the product listing): BUSPIRONE HYDROCHLORIDE, FLURAZEPAM, METHOTRIMEPRAZINE, TRIAZOLAM 28:24 Sedatives and Hypnotics

BUSPIRONE HYDROCHLORIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 10mg · Tab

FLURAZEPAM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 15mg, 30mg · Cap

METHOTRIMEPRAZINE

· 9 products · General benefit (5), Listed, not a benefit (4) · strengths: 25mg/mL, 2mg, 5mg, 25mg, 50mg · Inj Sol-1mL Pk, Tab

NITRAZEPAM

· 2 products · General benefit · strengths: 5mg, 10mg · Tab

PHENOBARBITAL

· 5 products · General benefit · strengths: 5mg/mL, 15mg, 30mg, 60mg, 100mg · Oral Elixir, Tab

TEMAZEPAM

· 2 products · General benefit · strengths: 15mg, 30mg · Cap

TRIAZOLAM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.125mg, 0.25mg · Tab

MIDAZOLAM

· 3 products · Listed, not a benefit (1), Limited Use, codes 495, 496 (2) · strengths: 5mg/mL · Inj Sol (with Preservative)

ESZOPICLONE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2mg, 3mg · Tab

ZOLPIDEM TARTRATE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · SL Tab

ZOPICLONE

· 40 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 3.75mg, 5mg, 7.5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:24
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: anxiety neurosis
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. OXAZEPAM · General benefit (3), Listed, not a benefit (3) 1 INDICATIONS APO-OXAZEPAM (oxazepam tablets) is indicated for the short-term symptomatic relief of excessive anxiety and tension in patients with anxiety neurosis. PM: https://pdf.hres.ca/dpd_pm/00072522.PDF; date SEP 05, 2023; DIN 00402680; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS TEVA-LORAZEPAM (lorazepam) is indicated for: • the short-term relief of manifestations of excessive anxiety in patients with anxiety neurosis. Anxiety and tension associated with the stresses of everyday life usually do not require treatment with anxiolytic drugs. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. Long-term use of TEVA-LORAZEPAM should be avoided in geriatric patients. Enhanced monitoring is recommended (see 7 WARNINGS AND PRECAUTIONS, Falls and fractures; 4 DOSAGE AND ADMINISTRATION, 4.1 Dosing considerations). https://pdf.hres.ca/dpd_pm/00070208.PDF PM date: March 05, 1985 Source product: TEVA-LORAZEPAM; DIN 00637742; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.